Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Cancer Prevention Pharmaceuticals Receives FAP Trial Advice

By Drug Discovery Trends Editor | July 29, 2011

Cancer Prevention Pharmaceuticals, Inc. received positive advice from the European Medicines Agency (EMA) regarding its Phase III trial in Familial Adenomatous Polyposis (FAP). 

The EMA advice included agreement on design features such as its clinically important endpoint, study duration, statistical analysis plan, and comparator arms.  The EMA’s advice is consistent with guidance received from the FDA earlier this year and the company is now poised to begin a multinational study in FAP that will be used to support registration in both European Union and the United States. 
 
The CPP study is a departure from previous and traditional trial designs that focused on “polyp counting.”  Celecoxib was previously approved for FAP using the polyp counting endpoint with only a 28% reduction in polyp burden but unfortunately never translated into a standard of care or proven clinical benefit.  The FAP indication was recently withdrawn from the Celecoxib label.  In a departure from these endpoints, CPP will target a delay in FAP-related events such as surgical events, duodenal disease, cancer, and death , which are now accepted by the regulators as “clinically meaningful.”

Release Date: July 27, 2011
Source: Cancer Prevention Pharmaceuticals, Inc 


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE